CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.12% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money
4283.2
0.9%
Market Trading Hours* (UTC) Opens on Tuesday at 00:00

Tue - Fri: 00:00 - 02:30 03:30 - 06:25

  • Summary
  • Historical Data
Trading сonditions
Spread 11.0
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.012355 %
Charges from full value of position ($-2.35)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.012355%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.009867 %
Charges from full value of position ($-1.87)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.009867%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency JPY
Margin 5.00%
Stock exchange Japan
Commission on trade 0%

Key Stats
Prev. Close 4244.8
Open 4274.4
1-Year Change -31.44%
Day's Range 4250.9 - 4296.8
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 21, 2025 4283.2 14.7 0.34% 4268.5 4298.8 4241.2
Feb 20, 2025 4244.8 -72.6 -1.68% 4317.4 4317.6 4219.2
Feb 19, 2025 4325.7 -32.3 -0.74% 4358.0 4369.6 4306.0
Feb 18, 2025 4368.7 43.7 1.01% 4325.0 4377.8 4286.1
Feb 17, 2025 4341.9 -20.0 -0.46% 4361.9 4383.7 4337.9
Feb 14, 2025 4353.7 -50.9 -1.16% 4404.6 4415.6 4325.7
Feb 13, 2025 4403.6 0.8 0.02% 4402.8 4478.2 4391.9
Feb 12, 2025 4313.8 -123.7 -2.79% 4437.5 4441.4 4296.8
Feb 10, 2025 4459.6 -36.4 -0.81% 4496.0 4532.7 4360.8
Feb 7, 2025 4498.6 37.8 0.85% 4460.8 4658.7 4443.1
Feb 6, 2025 4504.5 112.9 2.57% 4391.6 4505.9 4387.2
Feb 5, 2025 4367.7 -49.9 -1.13% 4417.6 4418.7 4344.2
Feb 4, 2025 4451.2 -17.4 -0.39% 4468.6 4509.9 4438.2
Feb 3, 2025 4412.6 -25.0 -0.56% 4437.6 4440.7 4382.3
Jan 31, 2025 4623.4 -13.1 -0.28% 4636.5 4638.7 4598.9
Jan 30, 2025 4626.4 25.9 0.56% 4600.5 4639.3 4588.0
Jan 29, 2025 4621.9 -76.5 -1.63% 4698.4 4707.9 4592.9
Jan 28, 2025 4697.2 33.7 0.72% 4663.5 4726.5 4661.0
Jan 27, 2025 4673.0 63.0 1.37% 4610.0 4689.5 4610.0
Jan 24, 2025 4516.0 17.0 0.38% 4499.0 4566.9 4488.0

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Eisai Co., Ltd. Company profile

About Eisai Co., Ltd

Eisai Co., Ltd. is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Oceania), Asia and Latin America (South Korea, Taiwan, Hong Kong, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.

Financial summary

BRIEF: For the nine months ended 31 December 2021, Eisai Co., Ltd revenues increased 13% to Y565.33B. Net income applicable to common stockholders increased 34% to Y60.36B. Revenues reflect Other Business segment increase from Y43.85B to Y92.54B, Pharmaceutical Business segment increase of 3% to Y449.48B, China segment increase of 25% to Y83.14B, America segment increase of 13% to Y125.19B, Asia/Latin America segment increase of 10% to Y38.04B.

Equity composition

FY'99-02 WAS & FY'04 DWAS were estimated. FY'03 DWAS was adjusted to reflect reported DEPS. FY'04-06 1Q&3Q WAS & O/S were estimated. 12/05 DPS estimated. FY'08 Q1&Q3 DWAS were estimated. FY'08 Q1&Q3 WAS = O/S. FY'11 Q3 DWAS estimated.

Industry: Pharmaceuticals (NEC)

エーザイ本館
小石川4-6-10
BUNKYO-KU
TOKYO-TO 112-8088
JP

People also watch

ETH/USD

2,779.27 Price
+5.290% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

Gold

2,936.56 Price
-0.110% 1D Chg, %
Long position overnight fee -0.0149%
Short position overnight fee 0.0067%
Overnight fee time 22:00 (UTC)
Spread 0.30

US100

21,594.40 Price
-2.120% 1D Chg, %
Long position overnight fee -0.0235%
Short position overnight fee 0.0013%
Overnight fee time 22:00 (UTC)
Spread 7.0

BTC/USD

96,674.75 Price
+1.390% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

Still looking for a broker you can trust?

Join the 690,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading